Callan Family Office LLC Invests $298,000 in Humana Inc. $HUM

Callan Family Office LLC bought a new position in shares of Humana Inc. (NYSE:HUM - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,220 shares of the insurance provider's stock, valued at approximately $298,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Humana by 8.9% in the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider's stock valued at $3,697,222,000 after purchasing an additional 1,143,662 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Humana by 3,257.5% in the 1st quarter. AQR Capital Management LLC now owns 1,162,600 shares of the insurance provider's stock valued at $307,624,000 after acquiring an additional 1,127,973 shares during the period. Nuveen LLC purchased a new stake in Humana during the 1st quarter worth $171,220,000. Dodge & Cox increased its stake in Humana by 5.5% during the 1st quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider's stock worth $2,845,830,000 after buying an additional 557,175 shares during the period. Finally, Pzena Investment Management LLC grew its holdings in Humana by 6.1% during the 1st quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider's stock worth $1,013,133,000 after acquiring an additional 219,541 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Price Performance

Shares of Humana stock opened at $266.78 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $315.35. The firm has a fifty day moving average price of $280.37 and a two-hundred day moving average price of $258.16. The company has a market cap of $32.09 billion, a PE ratio of 20.47, a price-to-earnings-growth ratio of 1.53 and a beta of 0.42.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The business had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.Humana's revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the business posted $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. Analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.3%. Humana's dividend payout ratio (DPR) is 27.17%.

Analysts Set New Price Targets

Several research firms have recently commented on HUM. Morgan Stanley decreased their price target on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating for the company in a report on Thursday, July 31st. Truist Financial set a $300.00 price target on shares of Humana in a research report on Tuesday. Wall Street Zen lowered shares of Humana from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Robert W. Baird dropped their price objective on shares of Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research note on Friday, July 25th. Finally, Guggenheim reiterated a "buy" rating on shares of Humana in a research note on Friday, October 3rd. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $297.58.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.